openPR Logo
Press release

Lawsuit filed for Investors in shares of Reckitt Benckiser Group plc (OTC: RBGLY)

08-05-2019 09:02 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Reckitt Benckiser Group plc (OTC: RBGLY) shares.

A lawsuit was filed on behalf of investors in Reckitt Benckiser Group plc (OTC: RBGLY) shares.

An investor, who purchased shares of Reckitt Benckiser Group plc (OTC: RBGLY), filed a lawsuit over alleged violations of Federal Securities Laws by Reckitt Benckiser Group plc.

Investors who purchased shares of Reckitt Benckiser Group plc (OTC: RBGLY) have certain options and for certain investors are short and strict deadlines running. Deadline: September 13, 2019. OTC: RBGLY investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

London based Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. On July 24, 2017, the Company announced in connection with its second quarter 2017 financial results, that it had recorded a £318 million charge related to ongoing U.S. Department of Justice and U.S. Federal Trade Commission investigations into its former Reckitt Pharma operations.

On February 19, 2018, Reckitt announced, in connection with its full year 2017 financial results, that it had recorded an exceptional charge of £296 million due to the investigations, and that the investigations now also involved the California Department of Insurance.

On April 9, 2019, the DOJ filed a criminal indictment against Reckitt Pharma (now known as Indivior), which detailed a multi-billion-dollar scheme to defraud the public and the Company’s investors through the marketing and sale of Suboxone Film.

Ultimately, Reckitt agreed to settle the federal investigations into its marketing and sale of Suboxone Film for $1.4 billion.

The plaintiff claims that between July 28, 2014 and April 9, 2019, the Reckitt and its most senior executives perpetrated a scheme, which generated over $3 billion in proceeds, to facilitate opiate abuse among U.S. consumers and mislead investors and the public regarding the health and safety risks of Reckitt’s new key opiate product, Suboxone Film.

the complaint alleges that in order to maintain and grow profits, senior executives at Reckitt devised a plan to switch prescribers from Suboxone Tablets to the Company’s new proprietary treatment, Suboxone Film. Suboxone Film had similar active ingredients to Suboxone Tablets, however it was dispensed in a thin film placed under the tongue and stored in single-use foil wrappings. Executives planned to create a marketing campaign that touted the purported safety benefits of Suboxone Film over Suboxone Tablets in order to prevent generic competition. Key to this campaign was fabricating safety concerns with existing treatments in order to delay the entry and approval of generics for Suboxone Tablets. Defendants’ scheme to fraudulently inflate sales of Suboxone Film was a success. Between 2010 and 2014, the Company’s revenues from sales of the drug increased ten-fold to over $840 million annually.

Those who purchased shares of Reckitt Benckiser Group plc (OTC: RBGLY) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Reckitt Benckiser Group plc (OTC: RBGLY) here

News-ID: 1818215 • Views: 298

More Releases from Shareholders Foundation

Investigation announced for Investors in Genworth Financial, Inc. (NYSE: GNW)
An investigation was announced concerning potential securities laws violations by Genworth Financial, Inc. in connection with certain financial statements. Investors who purchased shares of Genworth Financial, Inc. (NYSE: GNW), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Genworth Financial, Inc. (NYSE: GNW) concerning whether a
Investigation announced for Long-Term Investors in shares of Dropbox, Inc. (NASD …
An investigation was announced for investors in shares of Dropbox, Inc. (NASDAQ: DBX) concerning potential breaches of fiduciary duties by certain directors of Dropbox, Inc.. Investors who are current long term investors in Dropbox, Inc. (NASDAQ: DBX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: DBX stocks follows
Deadline in Lawsuit for Investors in shares of Trulieve Cannabis Corp. (OTC: TCN …
The Shareholders Foundation announced that a deadline is coming up on February 28, 2020 in the lawsuit filed for certain investors of Trulieve Cannabis Corp. (OTC: TCNN) over alleged securities laws violations by Trulieve Cannabis Corp. Investors who purchased shares of Trulieve Cannabis Corp. (OTC: TCNN) have certain options and there are strict and short deadlines running. Deadline: February 28, 2020. OTC: TCNN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Investigation announced for Investors in shares of Canaan Inc. (NASDAQ: CAN)
An investigation was announced concerning potential securities laws violations by Canaan Inc. in connection with certain financial statements. Investors who purchased shares of Canaan Inc. (NASDAQ: CAN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Canaan Inc. (NASDAQ: CAN regarding its business, its prospects and its operations were materially

All 5 Releases


More Releases for Reckitt

Interview released with Reckitt Benckiser, speaker at Pain Therapeutics 2019
SMi reports: An exclusive interview with Dalma Sugár, Global Medical Affairs Director, Reckitt Benckiser just ahead of SMi’s 19th Annual Pain Therapeutics Conference, taking place this May in London. SMi Group are delighted to host the exclusive conference on Pain Therapeutics on the 13th and 14th May 2019 in London, which will bring in expert voices from those at the forefront of technological innovation and analgesic therapies. The 2019 agenda features
Cold Remedies Market Analysis (2019- 2025)| Johnson & Johnson, GlaxoSmithKline, …
Los Angeles, United State, Feb 21, 2019- This research study is one of the most detailed and accurate ones that solely focus on the global Cold Remedies market. It sheds light on critical factors that impact the growth of the global Cold Remedies market on several fronts. Market participants can use the report to gain a sound understanding of the competitive landscape and strategies adopted by leading players of the
Antacids Market Analysis (2019 - 2025)| AstraZeneca, Takeda Pharmaceutical, Pfiz …
The global Antacids market report offers fine intelligence that prepares market players to compete well against their toughest competitors on the basis of growth, sales, and other vital factors. The research study lays emphasis on key growth opportunities and market trends apart from critical market dynamics including market drivers and challenges. With the help of this report, interested parties can equip themselves to adapt according to the changes in the
Global Antiseptic Mouthwash Market 2018: Key Players – Crest, Reckitt Benckise …
Summary WiseGuyReports.com adds “Antiseptic Mouthwash Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database. This report provides in depth study of “Antiseptic Mouthwash Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Antiseptic Mouthwash Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as
Surface Disinfectant Market 2016 – Top Industry Players as – 3M STERIS plc R …
Disinfectants are chemical substances that are applied to non-living objects and surfaces of the floor to destroy microorganisms. The essential use of disinfectants is part of a strategy to prevent infectious diseases. Here surfaces are considered noncritical items and they contact intact skin. The use of noncritical items or contact with noncritical surfaces carries little risk of causing an infection in humans. Surface should be clean in hospital, clinics and
Pericarditis Market BY Business Players: Pfizer, Astrazeneca, Bayer, Reckitt Ben …
Pericarditis is inflammation of the pericardium (the fibrous sac surrounding the heart). Symptoms typically include sudden onset of sharp chest pain. The pain may also be felt in the shoulders, neck, or back. It is typically better sitting up and worse with lying down or breathing deep. Other symptoms may include fever, weakness, palpitations, and shortness of breath. Occasionally onset of symptoms is gradual. Treatment in most cases is with